Form 4: Recursion Pharmaceuticals Director Dar Zavain Receives Stock and Option Grants

Director Dar Zavain received restricted stock units and stock options from Recursion Pharmaceuticals on June 3, 2024.

Summary

• On June 3, 2024, Dar Zavain, a director of Recursion Pharmaceuticals, received a grant of 13,097 shares of Class A Common Stock.
• These restricted stock units will vest on the earlier of June 3, 2025, or the day prior to the Issuer's 2025 annual meeting of stockholders, contingent upon continued service.
• Additionally, Zavain received a stock option to purchase 26,193 shares of Class A Common Stock at an exercise price of $8.59.
• These options will vest and become exercisable on the earlier of June 3, 2025, or the date of the Issuer's 2025 Annual Meeting of Stockholders, also subject to continued service.
• Following these transactions, Zavain beneficially owns 102,153 shares of Class A Common Stock and options for 26,193 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects standard compensation practices and aligns director interests with shareholders. There are no indications of negative events or concerns.

Positives

• The grant of restricted stock units and stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages continued service to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the granted securities.

Industry Context

Stock grants and options are common forms of compensation for directors in publicly traded companies, aligning their interests with shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Director compensation packages often include a mix of cash and equity.
• The size and structure of the equity grants are generally benchmarked against peer companies in the biotechnology or pharmaceutical industry to attract and retain qualified board members.
• Companies like Amgen, Gilead, and Biogen also use similar equity-based compensation for their directors.

Stakeholder Impact

• The equity grants align the director's interests with those of the shareholders, potentially leading to better corporate governance and decision-making.
• The grants have no immediate impact on employees, customers, suppliers, or creditors.

Key Dates